CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurocrine Biosciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurocrine Biosciences, Inc.
12780 El Camino Real
Phone: (858) 617-7600p:858 617-7600 SAN DIEGO, CA  92130-2042  United States Ticker: NBIXNBIX

Business Summary
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board William H.Rastetter 75 5/1/2011 2/8/2010
Chief Executive Officer, Director Kevin C.Gorman 65 11/20/2017 1/1/2003
Chief Financial Officer Matthew C.Abernethy 43 11/29/2017 11/29/2017
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Diurnal Group PLC Heath Park CARDIFF United Kingdom

Business Names
Business Name
Diurnal Europe B.V.
Diurnal Group Limited
Diurnal Group PLC
8 additional Business Names available in full report.

General Information
Number of Employees: 1,400 (As of 12/31/2023)
Outstanding Shares: 99,507,490 (As of 2/5/2024)
Shareholders: 43
Stock Exchange: NASD
Federal Tax Id: 330525145
Fax Number: (858) 617-7602
Email Address: ir@neurocrine.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024